PERSPECTA

News from every angle

← Back to headlines

Novo Nordisk Shares Drop After Heart Medicine Trial Disappointment

Novo Nordisk's shares experienced a significant decline after its heart medicine, ziltivekimab, failed to meet its primary endpoint in a phase 2 trial. The disappointing research data led to a sharp drop in the company's stock value.

31 Jul, 11:43 — 31 Jul, 11:43
PostShare

Sources

Showing 1 of 5 sources
cnbcMostly Factual2h ago

Novo Nordisk shares dive 9% after heart medicine fails trial

Read full article →

Coverage Timeline

First report: cnbc · 31 Jul, 11:43Full coverage: 5 · 13mWindow: 13m
Left-leaningCenterRight-leaning
cnbc31 Jul, 11:43First to report

Novo Nordisk shares dive 9% after heart medicine fails trial

vg31 Jul, 11:50

Novo Nordisk-aksjen raser etter studie-bommert

dr-dk31 Jul, 11:51

Novo Nordisk-aktien styrtdykker efter skuffende forsøg med hjertemedicin

politiken31 Jul, 11:55

Novo-aktien tager stort dyk efter studie med skidt nyt

berlingske31 Jul, 11:56Latest update

Novo-aktien dykker efter skuffende forskningsdata om hjertemedicin

Related Stories

Zambales Capital Iba Seeks Cityhood, Income Rule Waiver

just now

Man Arrested in Novi Sad for Illegal Sales and Unpaid Suppliers

12m ago

Rise on Wall Street – Apple falls heavily after earnings release

13m ago

Paks Nuclear Plant Reduces Output Due to Low Danube Water Levels

14m ago